A phase 1 study of the PI3K inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

✍ Scribed by Kahl, B. S.; Spurgeon, S. E.; Furman, R. R.; Flinn, I. W.; Coutre, S. E.; Brown, J. R.; Benson, D. M.; Byrd, J. C.; Peterman, S.; Cho, Y.; Yu, A.; Godfrey, W. R.; Wagner-Johnston, N. D.

• Book ID: 125435999
• Publisher: American Society of Hematology
• Year: 2014
• Tongue: English
• Weight: 561 KB
• Volume: 123
• Category: Article
• ISSN: 0006-4971
• DOI: 10.1182/blood-2013-11-537555